Heart, Lung and Circulation
Volume 16, Issue 4 , Pages 290-294 , August 2007

N-Terminal Pro Brain Natriuretic Peptide to Predict Prognosis in Dilated Cardiomyopathy with Sinus Rhythm

Received 20 July 2006 ,Revised 23 November 2006 ,Accepted 5 February 2007.

References 

  1. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998;97:1921–1929
  2. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126–1130
  3. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. JACC. 2004;43:635–641
  4. Yvorchuk KJ, Davies RA, Chan KL. Measurement of left ventricular ejection fraction by acoustic quantification and comparison with radionuclide angiography. Am J Cardiol. 1994;74:1052
  5. Kolias TJ, Aaronson KD, Armstrong WF. Doppler derived dP/dt and −dP/dt predict survival in congestive heart failure. J Am Coll Cardiol. 2000;36:1594–1599
  6. Recusani F, Bargiggia GS, Yoganathan AP, Raisaro A, Valdes-Cruz LM, Sung HW, et al. A new method for quantification of regurgitant flow rate using colour Doppler flow imaging of the flow convergence region proximal to a discrete orifice: An in vitro study. Circulation. 1991;83:594–599
  7. Shiota T, Jones M, Teien DE, Yamada I, Passafini A, Ge S, et al. Evaluation of mitral regurgitation using a digitally determined colour Doppler flow convergence ‘centerline’ acceleration method: Studies in an animal model with quantified mitral regurgitation. Circulation. 1994;89:2879–2886
  8. Konstam MA. Progress in heart failure management? Lessons from the real world. Circulation. 2000;102:1076–1082
  9. Deedwania PC. The key to unravelling the mystery of mortality in heart failure: An integrated approach. Circulation. 2003;107:1719–1727
  10. Chen HH, Burnett JC. The natriuretic peptides in heart failure diagnostic and therapeutic potentials. Proc Assoc Am Physicians. 1999;111:406–416
  11. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left ventricular systolic dysfunction. Lancet. 1998;351:9–13
  12. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509–516
  13. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141(3):367–374
  14. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547–1552
  15. Massie BM, Fisher SG, Radford M, Deedwania PC, Singh BN, Fletcher RD, et al. The CHF-STAT Investigators. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure (published erratum appears in Circulation 1996;94:2668). Circulation. 1996;93(21):28–34
  16. Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara T, Suga S, et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation. 1993;88:372–380
  17. Briguori C, Betocchi S, Manganelli F, Gigante B, Losi MA, Ciampi Q, et al. Determinants and clinical significance of natriuretic peptides in hypertrophic cardiomyopathy. Eur Heart J. 2001;22:1328–1336
  18. Vrtovec B, Delgado R, Zewail A, Thomas CD, Richartz BM, Radovancevic B. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation. 2003;107:1764–1769
  19. Hansen DE, Craig CS, Hondeghem LM. Stretch-induced arrhythmias in the isolated canine ventricle: evidence for the importance of mechanoelectrical feedback. Circulation. 1990;81:1094–1105
  20. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1587–1593
  21. Rihal CS, Nishimura RA, Hatle LK, Bailey KR, Tajik AJ. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. Circulation. 1994;90:2772–2779

PII: S1443-9506(07)00125-4

doi: 10.1016/j.hlc.2007.02.083

Heart, Lung and Circulation
Volume 16, Issue 4 , Pages 290-294 , August 2007

Article Tools

* Image Usage & Resolution